ライフサイエンスコーパス: academia

1 d to windstorms are an understudied topic in academia.

2 how science is conducted in industry versus academia.

3 revent more effective application of FBDD in academia.

4 most PDMS and plastic molding techniques in academia.

5 e attention of researchers from industry and academia.

6 but is sometimes used less systematically in academia.

7 pefully be useful for those pursuing FBDD in academia.

8 icologists, across government, industry, and academia.

9 toral researchers were focused on careers in academia.

10 debates about women's underrepresentation in academia.

11 y used as an oxidizing agent in industry and academia.

12 ct uniquely predictive of gender gaps across academia.

13 butes to the underrepresentation of women in academia.

14 tions between the biotechnology industry and academia.

15 ue in a pipeline traditionally geared toward academia.

16 ile empowering discovery across industry and academia.

17 r many research and clinical applications in academia.

18 with the majority (>60%) being supported by academia.

19 epresents a flashpoint for discussion across academia.

20 s both in the pharmaceutical industry and in academia.

21 and strengthening the societal leadership of academia.

22 emand the study of the role of mentorship in academia.

23 talented residents interested in careers in academia.

24 and institutional review board approval for academia.

25 n in the biomedical workforce, especially in academia.

26 requires participation of both industry and academia.

27 Organizational changes are also under way in academia.

28 bers of the FDA, other federal agencies, and academia.

29 ns the underrepresentation of some groups in academia.

30 dustry and, in some cases, to then return to academia.

31 taken up by more groups in both industry and academia.

32 nology and spin-off companies originating in academia.

33 earch, teaching, and service in industry and academia.

34 t a prerequisite for a career in science and academia.

35 despite their prevalent use in industry and academia.

36 ies-and the people who do them-are valued in academia.

37 in biomedical research in both industry and academia.

38 hether collaborators belonged to industry or academia.

39 peline that perpetuate racial disparities in academia.

40 at can be taken to curb sexual harassment in academia.

41 drugs have their origin in small biotech or academia.

42 an overview of neuroscience research beyond academia.

43 lic repositories has become best practice in academia.

44 nes remains a challenge in both industry and academia.

45 campaigns in the pharmaceutical industry and academia.

46 ise them about careers inside and outside of academia.

47 Women were more concentrated in academia (22% vs 14%, P = .009) and breast imaging (27%

48 Economic partnerships between industry and academia accelerate medical innovation and enhance patie

49 ender disparities appear to be decreasing in academia according to a number of metrics, such as grant

50 holders including public, administration and academia alike is required to counter the growing threat

51 nal organisations, national governments, and academia all have responsibilities in ensuring that data

52 provided a platform for global experts from academia, allergy clinics, regulatory authorities and in

53 rtunities, and movement between industry and academia-almost unheard of two decades ago-now occurs re

54 ed they would spend most of their careers in academia and 15% thought research would be their major f

55 many are now considering careers outside of academia and are aware of numerous exciting career oppor

56 flexible and better connected to research in academia and biotechnology firms.

57 In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed t

58 on of the Open AUC MWL detector developed in academia and first introduced in 2006 by Bhattacharya et

59 -based research centers and researchers from academia and government will undoubtedly continue to inc

60 lending is a common practice in industry and academia and has a large economic advantage.

61 Contributions from large companies, academia and high-tech start-ups are used to elucidate w

62 industries work alongside the scientists in academia and in government to set priorities, make decis

63 n a major goal for many laboratories both in academia and in industry.

64 ibly changed for the modern chemist, both in academia and in industry.

65 spectrometry (MS) is becoming widely used in academia and in pharmaceutical and biotechnology industr

66 nhibitors has been intensely pursued both in academia and in pharmaceutical companies.

67 ) is the focus of intensive research both in academia and in pharmaceutical companies.

68 bute to strengthening biomedical research in academia and in the biotechnology and pharmaceutical ind

69 llenges for researchers and practitioners in academia and industries, in terms of rising demand for s

70 Certainly research efforts, in academia and industry alike, are ongoing with the main a

71 potentials, it poses several challenges for academia and industry analysts alike.

72 cid and aryl halides are widely used in both academia and industry and are strategically important in

73 high-throughput experimentation protocols in academia and industry are adopted.

74 Scientists in both academia and industry are now using biosensors in areas

75 In response, groups within academia and industry are working to improve the sensory

76 alyze multidisciplinary partnerships between academia and industry as scientists attempt to merge the

77 eives a lot of attention from researchers in academia and industry as this technology provides reduce

78 Speakers from academia and industry came together to provide up-to-dat

79 lysis, and manuscript preparation where both academia and industry can supply important insights.

80 sis and has been intensively investigated in academia and industry for a century.

81 to preempt growing concerns arising in both academia and industry for data-driven applications of bi

82 without LD are available to investigators in academia and industry for evaluation or development of n

83 Finally, harmonization between academia and industry for more clinically relevant precl

84 th of "Big Pharma," the relationship between academia and industry has changed.

85 Functional genomics research within both academia and industry has led to the identification of m

86 In recent years, both academia and industry have foreseen the storage of natur

87 ts and the practitioners of this art both in academia and industry hopefully will continue to design

88 growing acceptance of relationships between academia and industry in the life sciences, systematic,

89 ssess the evolution of relationships between academia and industry over the past decade.

90 the result of intense collaboration between academia and industry over the past several decades, cul

91 has been receiving increasing attention from academia and industry over the recent years.

92 ed for MS-based protein footprinting in both academia and industry owing to its high throughput capab

93 A total of 104 groups from academia and industry participated, contributing 853 sub

94 Increasingly, academia and industry seek to collaborate, and share res

95 hnologies for data management from computing academia and industry to explore improvement solutions.

96 ombines interdisciplinary knowledge from the academia and industry to facilitate technological conver

97 resting positions, spanning from research in academia and industry to grant-making for a philanthropi

98 r sustainable chemicals and fuels has pushed academia and industry to search for alternative feedstoc

99 These models are already being utilized by academia and industry to search for genetic and chemical

100 nt years reporter genes have been applied in academia and industry to the study of ligand efficacy an

101 ence which included over 250 members of both academia and industry was a great opportunity to learn a

102 mentary solutions that leverage expertise of academia and industry were proposed to address them.

103 Key research thrusts in both academia and industry will speed this transition, and le

104 al interest to the chemistry community (both academia and industry) as it contains an extensive overv

105 erent type of relationship is needed between academia and industry, and also within industry, to prom

106 MRI-based technologies, closer ties between academia and industry, and an expanded endeavour to shar

107 via extensive collaborative research between academia and industry, applying ingenious solutions and

108 ld is gaining increasing interests from both academia and industry, barriers such as supersensitive d

109 ogy required for the work is similar between academia and industry, but the way in which these skills

110 Owing to their wide application in academia and industry, new methods and strategies for th

111 esearch and development is underway, both in academia and industry, to meet the demand for electric v

112 earch activity across the globe, and between academia and industry, to translate scientific discoveri

113 gistered for the conference, drawn both from academia and industry, with a wide range in experience a

114 utics requires scientific activities in both academia and industry.

115 f disciplines has overcome obstacles in both academia and industry.

116 en a focus of many drug discovery efforts in academia and industry.

117 ealth, and thus attracts attention from both academia and industry.

118 -effects that draw great attention from both academia and industry.

119 government, non-governmental organisations, academia and industry.

120 a long-standing synthetic challenge in both academia and industry.

121 fic aspects of genetic ancestry inference in academia and industry.

122 and SPECT/CT systems have been developed in academia and industry.

123 differences between research environments in academia and industry.

124 I owe much of my success to my mentors from academia and industry.

125 in the investigation of natural products in academia and industry.

126 eneral proving ground for excellence both in academia and industry.

127 research problems through exchanges between academia and industry.

128 d amidation and oxygenation processes in the academia and industry.

129 have received significant attention in both academia and industry.

130 canSAR is widely used internationally by academia and industry.

131 as attracted substantial attention from both academia and industry.

132 t the full spectrum of chemical syntheses in academia and industry.

133 e and more popular for elemental analysis in academia and industry.

134 duction of large-area graphene films in both academia and industry.

135 In bridging the gap between academia and large pharmaceutical companies, the biotech

136 Studies from both academia and pharmaceutical companies have identified co

137 Despite considerable interest from both academia and pharmaceutical companies in the discovery a

138 discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-

139 ce an invaluable tool to many researchers in academia and pharmaceutical industry.

140 at women face in moving through the ranks of academia and propose ways to increase women's representa

141 convened by the Council on Linkages Between Academia and Public Health Practice in 1995 to develop p

142 nd Clinical Immunology (EAACI), experts from academia and regulatory agencies met with chamber operat

143 m overspecialization, a practice nurtured in academia and reinforced by funders.

144 ties, public health initiatives, healthcare, academia and scientific research, and data monitoring an

145 er it is possible to combine motherhood with academia and still be successful and happy.

146 potassium have proved indispensable in both academia and technology.

147 k in partnership with both the scientists in academia and the government to identify a means of addre

148 icts of interest have driven a wedge between academia and the pharmaceutical and devices industries.

149 Research in both academia and the pharmaceutical industry has led to the

150 y the different medicinal chemistry teams in academia and the pharmaceutical industry to improve pote

151 racterized by intensive efforts, within both academia and the pharmaceutical industry, to introduce n

152 d and have moved into production mode within academia and the pharmaceutical industry.

153 has generated considerable interest in both academia and the pharmaceutical industry.

154 Early drug repurposing occurred in academia and was based on serendipitous observations or

155 ality adjusted life years, were supported by academia, and evaluated non-pharmaceutical interventions

156 is that different incentives drive industry, academia, and funding bodies.

157 More than 300 participants from industry, academia, and government attended the symposium, which f

158 other stakeholders, such as the government, academia, and health care providers.

159 ed engagement of scientists from government, academia, and industry enabled multiple unanticipated an

160 nd resources from philanthropic foundations, academia, and industry to advance therapeutic discovery

161 artnerships across governments, health care, academia, and industry, and with the public, are essenti

162 nts, and work with leaders from governments, academia, and organizations to address and reduce avoida

163 s grown from the National Health Service, UK academia, and other organisations.

164 h research funding and regulatory agencies), academia, and patient groups to discuss these challenges

165 This study characterizes government, academia, and private funding for gene therapy trials in

166 borative approach from physicians, industry, academia, and regulatory bodies supporting great innovat

167 xicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore

168 Strong cooperation between industry, academia, and research institutions will be required to

169 abase (FAOSTAT)], the Australian government, academia, and the food industry.With the use of the FAOS

170 fecting rural areas as well as large cities, academia, and the military.

171 w the outbreak response from the government, academia, and UN agencies in Larkana, Sindh, Pakistan.

172 and local governments; professional bodies; academia; and the pharmaceutical industry met to review

173 rug sales, partnerships between industry and academia are essential to achieve the full promise of he

174 Industry and academia are finally coming to terms with the fact that

175 zed, researchers in industry, government and academia are increasingly examining liquid crystalline m

176 eat promise for improving gender equality in academia around the globe.

177 Its relevance applies to both industry and academia as an inherently direct and sustainable strateg

178 Many research laboratories in academia as well as industry routinely create geneticall

179 crofluidics has attracted much interest from academia as well as industry, since it potentially offer

180 dations for improving political diversity in academia bear the danger of imposing political interests

181 at included representatives from government, academia, business, and civil society and included exper

182 tools, some of which have long histories in academia but are new to the field of public health and r

183 ure has been largely inaccessible to Western academia but contains important information that can sup

184 red for fundamental spectroscopic studies in academia but not in industrial processes.

185 he degree of intellectual freedom allowed in academia but offers an increased opportunity to see the

186 s how organizational changes in industry and academia can complement each other.

187 1), which brought together participants from academia, clinical practice, industry, and regulatory an

188 While scientists in academia continue to explore the multifactorial nature o

189 l solutions; and encourage synergies between academia; contract research, development and manufacturi

190 d discovery (FBLD) in industry as well as in academia creates a high demand for sensitive and reliabl

191 a public-private partnership among the FDA, academia, data owners, and the pharmaceutical industry t

192 a better feel for the challenges mothers in academia face, and the strategies that can be used to su

193 Multiple stakeholders, including academia, federal funding agencies, industry, scientific

194 r, the process by which devices arising from academia find their way to translation remains poorly un

195 cal development and funding of the study and academia for patient recruitment and participation in th

196 ntial to solve these issues which have beset academia for several decades.

197 , constitute a wake-up call for governments, academia, funders, and WHO to strengthen programmes and

198 ts, Local Authorities, Department of Health, academia, General Practice and Hospital Trusts and the t

199 dpoints, which requires collaboration across academia, government and industry.

200 It remains to be seen whether academia, government laboratories and contract houses wi

201 ists, toxicologists, and risk assessors from academia, government, and industry convened to discuss u

202 Methods This group convened experts from academia, government, and industry to review barriers to

203 hnology have recently regained popularity in academia, government, and industry.

204 equire concerted international efforts among academia, government, and industry.

205 ed Solutions to Obesity: What is the Role of Academia, Government, Industry, and Health care?" as a p

206 bmitted by over 450 professionals working in academia, government, industry, and nonprofit organizati

207 ) convened a think tank of stakeholders from academia, government, industry, and patient advocacy to

208 No one sector, academia, government, industry, or health care, has been

209 Wide consensus between academia, governmental regulators, and industry for furt

210 This porosity between industry and academia has created opportunities for more rapid transl

211 worst, the spawning of a company from within academia has the potential to use public employees, spac

212 ution Act," scientists in the government and academia have been able, in earnest, to consider what ty

213 Many life sciences trainees in academia have limited exposure to how the biotechnology/

214 epresenting government and private agencies, academia, health educators, and tobacco control experts)

215 gether communities who need these drugs with academia, health-care professionals, and pharmaceutical

216 will be achieved through interactions across academia, hospitals, patient associations, health data m

217 In academia, however, fewer women reach top leadership posi

218 e documented underrepresentation of women in academia in general and cell biology in particular.

219 0th century, etiological epidemiology within academia in high-income countries shifted its primary co

220 has attracted much attention in industry and academia in recent years.

221 ndations and standards for both industry and academia in the field of antituberculosis drug developme

222 ve effort is required, involving government, academia, industry and civil society at all levels.

223 ata submission from worldwide researchers at academia, industry and government agencies.

224 emergent challenges and offer suggestions to academia, industry and government on how best to expand

225 tools and data amongst scientists working in academia, industry and government.

226 isted of experts in xenotransplantation from academia, industry, and federal agencies, and the discus

227 A major focus of academia, industry, and global governmental agencies is

228 arizes the topics presented by speakers from academia, industry, and government intended to address t

229 of individuals with relevant expertise from academia, industry, and government to provide the nephro

230 stimulate and catalyze partnerships between academia, industry, and other sources of capital.

231 a think tank comprising representatives from academia, industry, and regulatory agencies convened to

232 uding representatives from patients' groups, academia, industry, and regulatory agencies-is aimed at

233 litated a meeting represented by clinicians, academia, industry, and regulatory agencies.

234 nt (March 2008) public meeting, experts from academia, industry, and regulatory bodies discussed seve

235 national multidisciplinary group from within academia, industry, and the National Institutes of Healt

236 in workshop convened scientific leaders from academia, industry, government and patient advocacy grou

237 unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully p

238 Representatives from academia, industry, regulatory agencies, and patient gro

239 vascular drug development, stakeholders from academia, industry, regulatory bodies, and government ag

240 these meetings, a wide range of experts from academia, industry, the nonprofit sector, and the U.S. g

241 d for a consensus statement of standards for academia-industry interactions from the scientists' pers

242 The NEWMEDS consortium, an academia-industry partnership, assembled a database of o

243 such strategies should be the rebalancing of academia-industry partnerships towards academic research

244 The rise in academia-industry relationships has been accompanied by

245 ally receive little education about industry-academia interactions.

246 ent in the hierarchical ladder of Australian academia is a considerable waste of government investmen

247 Academia is a vital source of innovation and discovery,

248 We show that success in academia is predictable.

249 lable upon request for non-commercial use in academia (local hit table binary and indices are at ftp:

250 faced with a range of competing pressures in academia, making self-management key to building a succe

251 derstanding how institutional changes within academia may affect the overall potential of science req

252 CSF Tetrad graduates with diverse careers in academia, medicine, industry, and publishing, we hope th

253 e National Cancer Institute (NCI), NASA, and academia met in Bethesda to discuss major lung cancer is

254 = 9) and national civil society (n = 7), and academia (n = 3) based in Indonesia (n = 6), Malaysia (n

255 from non-governmental organisations (n=10), academia (n=2), the Civil Service (n=1), and a local aut

256 These findings suggest that academia needs to carefully evaluate why these new polic

257 The relationship between industry and academia needs to evolve to maximize the opportunity.

258 with green chemistry leaders from industry, academia, nongovernmental institutions (NGOs), and gover

259 While industry and academia often partner for the performance of phase I st

260 er popular scoring functions in industry and academia on both prediction of binding affinity and "nat

261 economic tools are not used widely in either academia or industry.

262 in a peer-reviewed journal; to get a job in academia or money to run a lab, we present these publish

263 idated or generally accepted definition from academia or regulatory authorities for this relevant pol

264 of closer interactions between industry and academia, other issues, such as conflicts of interest (b

265 vital for culture collections, industry and academia; particularly when addressing issues of intelle

266 ications of HAART, with representatives from academia, patient community, US Food and Drug Administra

267 government, medical professional societies, academia, patient groups, and industry gathered to brain

268 ts representing the pharmaceutical industry, academia, product development partnerships, and regulato

269 a committee created through a partnership of academia, professional organizations, and industry, but

270 gative practices all-too-often still seen in academia, promoting best mentoring practices, and buildi

271 ng pathogens has become standard practice in academia, public health agencies, and large industries.

272 small-molecule screening in industry versus academia, recent developments in high-throughput screeni

273 t is possible to restore balance to industry-academia relationships, thereby promoting progress while

274 safe, productive, and vibrant environment in academia requires coordinated and collaborative input as

275 ation, more emphasis on commercialization by academia research field, and increased information on ho

276 government, industry, regulatory bodies, and academia should realign to ensure medical science is use

277 applied research, the roles of industry and academia, the concerns about xenotransplantation, and th

278 Within the ivory tower of academia, the coronavirus disease 2019 (COVID-19) pandem

279 On April 17, 2010, scientists from academia, the National Cancer Institute (NCI), and the F

280 e solutions, and encourage synergies between academia, the pharmaceutical industry, and contract rese

281 artnership comprised of representatives from academia, the pharmaceutical industry, and the federal g

282 Many simultaneous activities involving academia; the pharmaceutical, device, and biotechnology

283 ently been a major focus within industry and academia, this Perspective highlights examples of target

284 d this new initiative to enable industry and academia to change the vector control paradigm for malar

285 g discovery researchers in both industry and academia to identify all the possible indications for ea

286 harassment, particularly that pertaining to academia, to understand its underlying causes.

287 ment of both the pharmaceutical industry and academia towards the discovery of new chemotherapeutic a

288 first-rate example of collaboration between academia (University of California) and industry (Sangam

289 mpleted training (n = 192) were currently in academia versus 26% of nonparticipants (n = 676; P = .00

290 eflects both leadership and participation in academia, we examined temporal trends in women's authors

291 nvolving collaborations between industry and academia, we propose voluntary standards related to: 1)

292 ys an important role in both industry and in academia where selectivity, activity and stability are c

293 This development became very popular in academia, where instruments are not operated for you by

294 Increasing collaboration with academia will also become more important for accessing t

295 ooperation between industry, government, and academia will be key in establishing long-term strategie

296 to leverage the basic research expertise in academia with the pharmaceutical industry's knowledge in

297 peutics for neurodegenerative disease within academia, with a special focus on organizational issues.

298 iduals experience as they pursue a career in academia within seven STEM disciplines.

299 nd their knowledge and skills may be lost to academia without intervention.

300 for predoctoral and postdoctoral trainees in academia, yet little attention is paid to preparation fo